证券代码：688136 证券简称：科兴制药 公告编号：2025-046 科兴生物制药股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 科兴生物制药股份有限公司（以下简称"公司"）股票连续三个交易日 内（2025 年 7 月 1 日、7 月 2 日、7 月 3 日）收盘价格涨幅偏离值累计超过 30%， 属于股票交易异常波动。 经公司自查，并向公司控股股东、实际控制人进行书面询证，截至本公 告披露日，确认不存在关于公司的应披露而未披露的重大事项，公司日常经营情 况正常，未发生重大变化，所处的行业政策未发生重大调整。 公司股价短期波动幅度较大，公司特别提醒广大投资者，注意投资风险、 理性决策、审慎投资。 一、股票交易异常波动的具体情况 公司股票连续三个交易日内（2025 年 7 月 1 日、7 月 2 日、7 月 3 日）收盘 价格涨幅偏离值累计超过 30%，根据《上海证券交易所科创板股票异常交易实时 监控细则》的有关规定，属于股票交易异常波动的情形。 二、公司关注并核实的相关情况 ...

Market Performance - The Sci-Tech Innovation Board (STAR Market) index rose by 0.24%, closing at 984.95 points, with a total trading volume of 2.701 billion shares and a turnover of 90.146 billion yuan, resulting in a weighted average turnover rate of 1.52% [1] - Among the tradable stocks on the STAR Market, 365 stocks closed higher, with 5 stocks increasing by over 10% and 30 stocks rising between 5% and 10%. Conversely, 208 stocks closed lower [1] Turnover Rate Analysis - The distribution of turnover rates shows that 2 stocks had turnover rates exceeding 20%, 11 stocks had rates between 10% and 20%, 44 stocks had rates between 5% and 10%, 72 stocks had rates between 3% and 5%, 294 stocks had rates between 1% and 3%, and 165 stocks had rates below 1% [1] - The stock with the highest turnover rate was Xinyuren, which closed up by 4.80% with a turnover rate of 33.00% and a transaction amount of 594 million yuan. Huasheng Lithium Battery followed with a 15.36% increase and a turnover rate of 21.64% [1] Sector Performance - In terms of industry performance, the pharmaceutical and biotechnology sector had the most stocks with a turnover rate exceeding 5%, totaling 14 stocks. The electronics and power equipment sectors followed with 13 and 10 stocks, respectively [2] Capital Flow - Among the high turnover stocks, 34 stocks experienced net inflows of main funds, with the highest net inflows recorded for Bolite, Kexing Pharmaceutical, and Huiyu Pharmaceutical, amounting to 131 million yuan, 74.062 million yuan, and 60.026 million yuan, respectively [2] - Conversely, the stocks with the largest net outflows included Huicheng Co., Daqian Energy, and Sunshine Nuohe, with net outflows of 76.657 million yuan, 56.088 million yuan, and 45.416 million yuan, respectively [2] Leverage Fund Movements - A total of 47 stocks received net purchases from leveraged funds, with notable increases in financing balances for Tailin Micro, Daqian Energy, and Kexing Pharmaceutical, which saw increases of 108 million yuan, 6.698 million yuan, and 6.592 million yuan, respectively [2] - Stocks with significant decreases in financing balances included Rongchang Biological, Sunshine Nuohe, and Liyuanheng, with decreases of 115 million yuan, 21.505 million yuan, and 12.791 million yuan, respectively [2]

二、 回购股份的进展情况 《上海证券交易所上市公司自律监管指引第 7 证券代码：688136 证券简称：科兴制药 公告编号：2025-044 科兴生物制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购方案首次披露日 2025/3/19 回购方案实施期限 2025 年 3 月 17 日~2026 年 3 月 16 日 预计回购金额 3,000万元~6,000万元 □减少注册资本 √用于员工持股计划或股权激励 回购用途 □用于转换公司可转债 □为维护公司价值及股东权益 累计已回购股数 1,269,333股 累计已回购股数占总股本比例 0.64% 累计已回购金额 4,738.19万元 实际回购价格区间 23.14元/股~43.50元/股 一、 回购股份的基本情况 科兴生物制药股份有限公司（以下简称"公司"）于 2025 年 3 月 17 日召开第 二届董事会第二十一次会议，审议通过了《关于以集中竞价交易方式回购公司股 份方案的议案》，同意公司使用不低于人民币 3,000 万元（含），不超过人民币 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、交易概述 根据公司的整体经营规划，为进一步聚焦生物医药主赛道，降低管理成本， 提高资产运营效率，公司于2025年6月9日召开第二届董事会第二十五次会议、第 二届监事会第二十一次会议审议通过《关于转让全资子公司股权的议案》，公司 将持有的全资子公司深圳同安医药有限公司（以下简称"同安医药"）100%的 股权作价1,500万元转让给广西壮族自治区药物研究所有限公司（以下简称"广 西药研所"）。具体内容详见公司于2025年6月11日在上海证券交易所网站 （www.sse.com.cn）上披露的《关于转让全资子公司股权的公告》（公告编号： 2025-035）。 二、股权转让的进展情况 证券代码：688136 证券简称：科兴制药 公告编号：2025-045 科兴生物制药股份有限公司 关于转让全资子公司股权的进展公告 公司已根据协议的约定办理完成同安医药股权工商变更登记手续，公司不再 持有同安医药股权。 特此公告。 科兴生物制药股份有限公司董事会 2025 年 7 月 3 日 1 根 ...

| 回购方案首次披露日 | 2025/3/19 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 2025 3 3 | 月 | 17 | 日~2026 | 年 | 月 | 16 | 日 | | 预计回购金额 | 3,000万元~6,000万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 1,269,333股 | | | | | | | | | 累计已回购股数占总股本比例 | 0.64% | | | | | | | | | 累计已回购金额 | 4,738.19万元 | | | | | | | | | 实际回购价格区间 | 23.14元/股~43.50元/股 | | | | | | | | 一、回购股份的基本情况 科兴生物制药股份有限公司（以下简称"公司"）于 2025 年 3 月 17 日召开第 ...

Group 1 - The weight loss drug concept increased by 2.51%, ranking 6th among concept sectors, with 46 stocks rising, including Kexing Pharmaceutical, Yipinhong, and Lepu Medical, which rose by 15.62%, 14.72%, and 7.62% respectively [1][2] - The weight loss drug sector saw a net inflow of 576 million yuan, with 24 stocks receiving net inflows, and 8 stocks exceeding 50 million yuan in net inflow, led by Yipinhong with a net inflow of 168 million yuan [2][3] - The top stocks by net inflow rate include Taiankang, Kexing Pharmaceutical, and Yipinhong, with net inflow rates of 20.64%, 14.10%, and 13.25% respectively [3] Group 2 - The concept sectors with the highest daily gains include China Shipbuilding System at 4.90%, Cell Immunotherapy at 3.12%, and Innovative Drugs at 3.01%, while sectors like Electronic ID and Digital Currency experienced declines of -2.52% and -2.40% respectively [2] - The weight loss drug sector's performance is notable among other sectors, indicating a growing interest and investment in this area [1][2]

Core Viewpoint - The hepatitis concept sector has seen a 2.30% increase, ranking 10th among concept sectors, with significant gains from stocks like Guizhou Bailing, Weiming Pharmaceutical, and Kexing Pharmaceutical [1]. Group 1: Sector Performance - The hepatitis concept sector had 116 stocks rising, with Guizhou Bailing, Weiming Pharmaceutical, and *ST Sailong hitting the daily limit up [1]. - Notable gainers included Kexing Pharmaceutical, Yipin Hong, and Rejing Biological, which rose by 15.62%, 14.72%, and 11.60% respectively [1]. - The sector's performance was contrasted by declines in stocks like *ST Suwu, *ST Sihuan, and New Industry, which fell by 0.79%, 0.78%, and 0.48% respectively [1]. Group 2: Capital Inflow - The hepatitis concept sector attracted a net inflow of 790 million yuan, with 71 stocks receiving net inflows [1]. - Yipin Hong led the net inflow with 168 million yuan, followed by Guizhou Bailing and Kexing Pharmaceutical with net inflows of 158 million yuan and 97.8 million yuan respectively [1]. - The top three stocks by net inflow rates were Guizhou Bailing at 17.80%, Weiming Pharmaceutical at 16.28%, and Kexing Pharmaceutical at 14.10% [2].

Group 1 - The core point of the news is that Sinovac Biotech (科兴制药) announced a reduction in shareholding by its controlling shareholder, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. (科益医药), and its concerted actor, Deng Xueqin, which resulted in a decrease in their combined shareholding from 66.32% to 65.00% [1][2] - The reduction in shareholding was due to the implementation of a previously disclosed share reduction plan and the dilution of shares resulting from the 2022 restricted stock incentive plan [1][2] - The total number of shares held by Keyi Pharmaceutical and Deng Xueqin decreased from 131,778,347 shares to 129,767,472 shares, representing a reduction of 2,010,875 shares, or 1.32% of the total share capital [1][2] Group 2 - The equity change will not lead to a change in the controlling shareholder or actual controller of Sinovac Biotech [2] - Sinovac Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 14, 2020, with an initial public offering (IPO) of 49.6753 million shares at a price of 22.33 yuan per share [2] - The total amount raised from the IPO was 1.109 billion yuan, with a net amount of 999.5 million yuan, which was 710 million yuan less than the originally planned amount of 1.705 billion yuan [2][3]

Core Viewpoint - The A-share innovative drug sector experienced a significant surge on July 1, driven by favorable policy announcements from the National Medical Insurance Administration and the National Health Commission, which aim to support the high-quality development of innovative drugs [1][4]. Group 1: Market Performance - Frontier Biotech reached a 20% limit-up, with other companies like Guizhou BaiLing, Saily Medical, and AngliKang also hitting their limits [2]. - Notable stock performances included: - Frontier Biotech: 12.05 (+20.02%) - Kexing Pharmaceutical: 44.19 (+15.62%) - Yuyuan Pharmaceutical: 22.00 (+15.55%) - Shuyitai: 43.00 (+15.34%) - Rongchang Biotech: 68.39 (+13.04%) [3]. Group 2: Policy Support - The new measures encourage the use of medical insurance data for innovative drug research and development, enhancing collaboration among medical, insurance, and pharmaceutical sectors [4][6]. - The policy promotes the expansion of commercial health insurance investments in innovative drugs, establishing a new directory for innovative drugs that exceed basic insurance coverage [6]. - The National Medical Insurance Administration plans to streamline the application process for including drugs in both commercial and medical insurance directories, reducing the administrative burden on companies [6]. Group 3: Industry Outlook - The innovative drug sector is in a golden development phase, with over 20 first-class innovative drugs approved for market entry from January to May, marking a five-year high [7]. - Chinese pharmaceutical companies are accelerating their international expansion, with over 90 overseas licensing transactions expected in 2024, totaling over $50 billion [7]. - Significant licensing deals include: - 12.5 billion USD deal by 3SBio - 53.3 billion USD collaboration between CSPC and AstraZeneca - 42.3 billion USD agreement by Rongchang Biotech [7]. - Several biotech firms are increasing R&D investments through share placements, with funds directed towards global R&D pipelines [8]. Group 4: Investment Sentiment - Analysts agree on the sustainable growth potential of the innovative drug sector, emphasizing the "innovation + internationalization" trend as a core focus for the pharmaceutical industry [9]. - Investment opportunities are seen in the upstream pharmaceutical supply chain, advanced manufacturing, and healthcare services, with a focus on companies with strong growth potential and profitability [9].

Core Insights - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, focusing on the entire chain from research and development to payment systems [1] - The inclusion of innovative drug directories in commercial health insurance is expected to enhance the multi-tiered medical security system and provide economic support for the development of innovative drugs [1][2] - The stock market reacted positively, with significant gains in innovative drug concept stocks and ETFs, indicating strong investor interest and liquidity in this sector [1][2] Industry Developments - The establishment of a commercial insurance innovative drug directory marks a significant step in enhancing the role of commercial insurance in the multi-tiered medical security system, providing payment support for high-priced innovative drugs and medical devices [2] - The "18A" policy has catalyzed a wave of medical companies listing in Hong Kong, focusing on cutting-edge medical industry directions, which has attracted market attention and investment [2] Market Performance - The Hong Kong innovative drug ETF (513120) saw a rise of over 2%, with a trading volume of 4.1 billion yuan, leading the market in the pharmaceutical ETF category [1] - The latest scale of the Hong Kong innovative drug ETF reached 13.4 billion yuan, indicating its leading position in the market [1] - The innovative drug ETF (515120) also performed well, with a trading volume of 145 million yuan and a net inflow of nearly 200 million yuan over five consecutive days [1]